A detailed history of Great Lakes Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Great Lakes Advisors, LLC holds 10,407 shares of NBIX stock, worth $1.31 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,407
Previous 111,278 90.65%
Holding current value
$1.31 Million
Previous $15.3 Million 92.18%
% of portfolio
0.01%
Previous 0.14%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$114.58 - $153.15 $11.6 Million - $15.4 Million
-100,871 Reduced 90.65%
10,407 $1.2 Million
Q2 2024

Aug 05, 2024

SELL
$130.86 - $143.19 $567,801 - $621,301
-4,339 Reduced 3.75%
111,278 $15.3 Million
Q1 2024

May 08, 2024

SELL
$130.4 - $143.74 $6.24 Million - $6.88 Million
-47,868 Reduced 29.28%
115,617 $15.9 Million
Q4 2023

Feb 08, 2024

BUY
$106.07 - $132.76 $162,074 - $202,857
1,528 Added 0.94%
163,485 $21.5 Million
Q3 2023

Nov 07, 2023

BUY
$94.02 - $117.1 $11.4 Million - $14.2 Million
121,592 Added 301.23%
161,957 $18.2 Million
Q2 2023

Aug 10, 2023

SELL
$89.53 - $104.87 $3.88 Million - $4.55 Million
-43,349 Reduced 51.78%
40,365 $3.81 Million
Q1 2023

May 10, 2023

BUY
$94.11 - $123.02 $3.9 Million - $5.1 Million
41,488 Added 98.25%
83,714 $8.47 Million
Q4 2022

Feb 09, 2023

SELL
$106.72 - $127.06 $93,700 - $111,558
-878 Reduced 2.04%
42,226 $5.04 Million
Q3 2022

Nov 09, 2022

BUY
$92.03 - $107.81 $3.97 Million - $4.65 Million
43,104 New
43,104 $4.58 Million
Q4 2018

Feb 13, 2019

SELL
$68.32 - $124.36 $5.15 Million - $9.38 Million
-75,389 Closed
0 $0
Q3 2018

Nov 30, 2018

BUY
$98.88 - $125.85 $7.45 Million - $9.49 Million
75,389 New
75,389 $9.27 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Great Lakes Advisors, LLC Portfolio

Follow Great Lakes Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Lakes Advisors, LLC with notifications on news.